Improving the Efficiency of Clinical Pharmacology Studies
- PMID: 37350534
- DOI: 10.1002/cpdd.1274
Improving the Efficiency of Clinical Pharmacology Studies
Keywords: clinical pharmacology; drug development; first-in-human; model-informed drug development; new drugs.
Comment in
-
Commentary on Improving the Efficiency of Clinical Pharmacology Studies.Clin Pharmacol Drug Dev. 2023 Aug;12(8):775-778. doi: 10.1002/cpdd.1295. Epub 2023 Jun 28. Clin Pharmacol Drug Dev. 2023. PMID: 37378863 No abstract available.
References
-
- Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844-853.
-
- Kraft WK. Clinical pharmacology and the best use of public research investment. Clin Pharmacol Ther. 2022;111(6):1185-1188.
-
- Parasrampuria DA, Benet LZ. Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful. Basic Clin Pharmacol Toxicol. 2015;117(1):44-51.
-
- Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. Eur J Clin Pharmacol. 2014;70(9):1115-1122.
-
- Brown K, Etrouth S, Jayachandran P, et al. Diversity in clinical pharmacology: a call to action. Clin Pharmacol Ther. 2023;113(3):483-485.
MeSH terms
LinkOut - more resources
Full Text Sources